CapsoVision Q2 revenue rises on CapsoCam Plus capsules sales

CapsoVision

13/08/2026 21:17

Overview
US capsule endoscopy firm's Q2 revenue rose 10% yr/yr to $3.6 mln
Gross margin declined to 51% from 55% due to pricing pressure and higher tariffs
Operating expenses increased, mainly from clinical trials and public company costs

Outlook
Company anticipates FDA clearance of AI Highlights by end of Q3 2026, with U.S. launch soon after
CapsoCam Colon on track for 510(k) submission in Q4 2026

Result Drivers
HIGHER CAPSULE SALES - Co said a 13% increase in CapsoCam Plus capsules sold was the main driver of revenue growth
PRICING PRESSURE AND TARIFFS - Gross margin declined due to competitive pricing pressure and increased expenses from changes in U.S. trade policies and tariffs
HIGHER OPERATING COSTS - Operating expenses rose mainly from clinical trials, engineering services, public company costs, and stock-based compensation

Company press release: ID:nGNX5jF7T7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$3.64 mln
 
Q2 Gross Profit
 
$1.87 mln
 
Q2 Operating Income
 
-$7.58 mln
 
Q2 Pretax Loss
 
$7.48 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for CapsoVision Inc is $10.00, about 45.8% above its August 12 closing price of $6.86

Reuters Recommended Reads
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Aug 13 - LENSAR Q2 revenue rises 18%, returns to profit
Aug 12 - Germany's Medios H1 profit hit by pricing pressure; to buy 74% of Caelo to expand API

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)